News

RedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101

RedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101   RedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101 – Hebrew  

Read More...

RedHill Biopharma Reports Results for the Second Quarter of 2014

RedHill Biopharma Reports Results for the Second Quarter of 2014   RedHill Biopharma Reports Results for the Second Quarter of 2014 – Hebrew

Read More...

RedHill Biopharma to Host Second Quarter 2014 Financial Results Conference Call on July 24, 2014

RedHill Biopharma to Host Second Quarter 2014 Financial Results Conference Call on July 24 2014

Read More...

RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON from WILEX AG

RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON from WILEX AG   RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON from WILEX AG – Hebrew

Read More...

RedHill Biopharma Announces Positive Preliminary Pre-Clinical Data with RHB-104 for the Treatment of Type 1 Diabetes

RedHill Biopharma Announces Positive Preliminary Pre-Clinical Data with RHB-104 for the Treatment of Type 1 Diabetes

Read More...

RedHill Biopharma to Present at the 2014 BIO International Convention

RedHill Biopharma to Present at the 2014 BIO International Convention

Read More...

RedHill Biopharma to Present at the Wells Fargo Securities 9th Annual Healthcare Conference

RedHill Biopharma to Present at the Wells Fargo Securities 9th Annual Healthcare Conference

Read More...

RedHill Biopharma Announces New RHB-104 Patent in Japan and Provides Update on Phase III Crohn’s Program

RedHill Biopharma Announces New RHB-104 Patent in Japan and Provides Update on Phase III Crohn’s Program   RedHill Biopharma Announces New RHB-104 Patent in Japan and Provides Update on Phase III Crohn’s Program – Hebrew

Read More...

RedHill Biopharma to Present at Jefferies 2014 Global Healthcare Conference

RedHill Biopharma to Present at Jefferies 2014 Global Healthcare Conference

Read More...

RedHill Biopharma Announces FDA Clearance for Phase III Study with RHB-102 Planned to Commence in Q3/2014

RedHill Biopharma Announces FDA Clearance for Phase III Study with RHB-102 Planned to Commence in Q3 2014   RedHill Biopharma Announces FDA Clearance for Phase III Study with RHB-102 Planned to Commence in Q3 2014 – Hebrew

Read More...

News